News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
397,295 Results
Type
Article (18917)
Company Profile (114)
Press Release (378264)
Multimedia
Podcasts (48)
Webinars (11)
Section
Business (121028)
Career Advice (710)
Deals (23588)
Drug Delivery (80)
Drug Development (56304)
Employer Resources (67)
FDA (9808)
Job Trends (8564)
News (214333)
Policy (19883)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (8)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (2)
2024 Genetown Digital (4)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (3)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (907)
Accelerated approval (3)
Adcomms (11)
Allergies (49)
Alliances (30150)
ALS (60)
Alzheimer's disease (813)
Antibody-drug conjugate (ADC) (67)
Approvals (9851)
Artificial intelligence (162)
Autoimmune disease (15)
Automation (6)
Bankruptcy (225)
Best Places to Work (6611)
BIOSECURE Act (10)
Biosimilars (62)
Biotechnology (51)
Bladder cancer (50)
Brain cancer (20)
Breast cancer (152)
Cancer (1375)
Cardiovascular disease (111)
Career advice (621)
Career pathing (12)
CAR-T (96)
Cell therapy (258)
Cervical cancer (14)
Clinical research (47105)
Collaboration (497)
Compensation (221)
Complete response letters (19)
COVID-19 (1211)
CRISPR (30)
C-suite (145)
Cystic fibrosis (57)
Data (1488)
Denatured (15)
Depression (23)
Diabetes (157)
Diagnostics (3127)
Digital health (5)
Diversity (3)
Diversity, equity & inclusion (19)
Drug discovery (83)
Drug pricing (80)
Drug shortages (22)
Duchenne muscular dystrophy (68)
Earnings (51349)
Editorial (19)
Employer branding (5)
Employer resources (58)
Events (57246)
Executive appointments (470)
FDA (10632)
Featured Employer (22)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (389)
Gene editing (69)
Generative AI (14)
Gene therapy (192)
GLP-1 (441)
Government (2131)
Grass and pollen (3)
Guidances (36)
Healthcare (8304)
Huntington's disease (8)
IgA nephropathy (21)
Immunology and inflammation (59)
Indications (25)
Infectious disease (1285)
Inflammatory bowel disease (88)
Inflation Reduction Act (7)
Influenza (27)
Intellectual property (67)
Interviews (98)
IPO (10874)
IRA (34)
Job creations (2314)
Job search strategy (553)
Kidney cancer (7)
Labor market (14)
Layoffs (205)
Leadership (5)
Legal (4403)
Liver cancer (43)
Lung cancer (197)
Lymphoma (104)
Machine learning (2)
Management (22)
Manufacturing (202)
MASH (51)
Medical device (5442)
Medtech (5445)
Mergers & acquisitions (13138)
Metabolic disorders (424)
Multiple sclerosis (49)
NASH (16)
Neurodegenerative disease (46)
Neuropsychiatric disorders (7)
Neuroscience (1152)
NextGen: Class of 2025 (2679)
Non-profit (1204)
Northern California (1565)
Now hiring (7)
Obesity (225)
Opinion (158)
Ovarian cancer (60)
Pain (69)
Pancreatic cancer (51)
Parkinson's disease (102)
Partnered (11)
Patents (181)
Patient recruitment (67)
Peanut (22)
People (35193)
Pharmaceutical (67)
Pharmacy benefit managers (14)
Phase I (14219)
Phase II (20672)
Phase III (16073)
Pipeline (868)
Policy (85)
Postmarket research (1642)
Preclinical (5541)
Press Release (32)
Prostate cancer (67)
Psychedelics (17)
Radiopharmaceuticals (169)
Rare diseases (253)
Real estate (3184)
Recruiting (23)
Regulatory (14650)
Reports (19)
Research institute (945)
Resumes & cover letters (89)
Rett syndrome (4)
RNA editing (3)
RSV (19)
Schizophrenia (51)
Series A (70)
Series B (38)
Service/supplier (5)
Sickle cell disease (43)
Southern California (1422)
Special edition (7)
Spinal muscular atrophy (90)
Sponsored (19)
Startups (1989)
State (2)
Stomach cancer (8)
Supply chain (45)
Tariffs (23)
The Weekly (31)
United States (14012)
Vaccines (263)
Venture capitalists (19)
Weight loss (148)
Women's health (11)
Worklife (7)
Date
Today (66)
Last 7 days (288)
Last 30 days (1507)
Last 365 days (21792)
2025 (6202)
2024 (23163)
2023 (26078)
2022 (33043)
2021 (34276)
2020 (32185)
2019 (23603)
2018 (17974)
2017 (20129)
2016 (18371)
2015 (22004)
2014 (16825)
2013 (13797)
2012 (14600)
2011 (15378)
2010 (14158)
Location
Africa (421)
Alabama (25)
Alaska (3)
Arizona (92)
Arkansas (6)
Asia (28369)
Australia (5729)
California (3599)
Canada (1408)
China (375)
Colorado (167)
Connecticut (183)
Delaware (88)
Europe (54513)
Florida (573)
Georgia (92)
Idaho (14)
Illinois (300)
India (23)
Indiana (188)
Iowa (1)
Japan (123)
Kansas (65)
Kentucky (14)
Louisiana (5)
Maine (38)
Maryland (498)
Massachusetts (2799)
Michigan (73)
Minnesota (169)
Missouri (49)
Montana (12)
Nebraska (14)
Nevada (44)
New Hampshire (42)
New Jersey (1267)
New Mexico (10)
New York (1111)
North Carolina (620)
North Dakota (3)
Northern California (1565)
Ohio (91)
Oklahoma (4)
Oregon (21)
Pennsylvania (883)
Puerto Rico (10)
Rhode Island (15)
South America (666)
South Carolina (11)
Southern California (1422)
Tennessee (68)
Texas (537)
Utah (84)
Virginia (101)
Washington D.C. (38)
Washington State (389)
West Virginia (2)
Wisconsin (23)
397,295 Results for "neuren pharmaceuticals limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Opinion
Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren
Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide catch up?
March 17, 2025
·
3 min read
·
Jia Jie Chen
Drug Development
Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome
Neuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome.
May 27, 2024
·
8 min read
Drug Development
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS).
December 18, 2023
·
7 min read
Deals
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591.
July 13, 2023
·
11 min read
Press Releases
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
April 7, 2025
·
4 min read
Press Releases
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
April 10, 2025
·
6 min read
Deals
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.
April 11, 2024
·
3 min read
Press Releases
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
February 11, 2025
·
8 min read
BioCapital
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
Vanda Pharmaceuticals Inc. announced that its Board of Directors has adopted a limited duration stockholder rights plan to protect stockholder interests and maximize value for all stockholders.
April 17, 2024
·
5 min read
Aurigene Pharmaceutical Services Limited, a global CRDMO, announces the opening of its biologics facility offering process development and clinical scale manufacturing capabilities
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley
June 3, 2024
·
4 min read
1 of 39,730
Next
